Rockefeller Capital Management L.P. Trims Position in Novo Nordisk A/S (NYSE:NVO)

Rockefeller Capital Management L.P. reduced its holdings in Novo Nordisk A/S (NYSE:NVO) by 12.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 484,586 shares of the company’s stock after selling 71,214 shares during the period. Rockefeller Capital Management L.P.’s holdings in Novo Nordisk A/S were worth $57,713,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in NVO. 1620 Investment Advisors Inc. purchased a new position in Novo Nordisk A/S during the second quarter valued at approximately $25,000. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Novo Nordisk A/S during the 2nd quarter worth approximately $25,000. Gilliland Jeter Wealth Management LLC increased its holdings in shares of Novo Nordisk A/S by 200.0% during the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after purchasing an additional 120 shares in the last quarter. Daiwa Securities Group Inc. acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at $28,000. Finally, Halpern Financial Inc. boosted its holdings in Novo Nordisk A/S by 113.0% during the second quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock worth $30,000 after buying an additional 113 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on NVO. BMO Capital Markets cut their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Trading Up 0.6 %

Shares of Novo Nordisk A/S stock opened at $106.80 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a twelve month low of $94.73 and a twelve month high of $148.15. The firm has a market capitalization of $479.27 billion, a PE ratio of 34.56, a P/E/G ratio of 1.37 and a beta of 0.42. The firm’s 50-day moving average price is $112.81 and its 200 day moving average price is $128.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.